In a significant advancement for asthma treatment, AstraZeneca, in partnership with Amgen, has received the coveted breakthrough therapy designation from the US Food and Drug Administration (FDA) for their innovative asthma drug, tezepelumab. This designation is specifically for the treatment of patients with severe asthma who do not exhibit an eosinophilic phenotype and are being […]
Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.
Sanofi and Regeneron Pharmaceuticals have announced a significant advancement in dermatological care with the U.S. Food and Drug Administration (FDA) approving Dupixent (dupilumab) for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. This marks Dupixent as the first biologic medication approved for patients who have not responded adequately to traditional topical prescription treatments […]